Statistics from Altmetric.com
Autoimmunity and inflammation are controlled in part by regulatory B cells expressing interleukin 10 (IL-10). Since, one of the characteristic of CD5 B cells lies in their capacity to produce IL-10, the aim of the subject was to characterise the transcription factors (TF) involved.
To address this question stably transfected CD5 B cells expressing the cell surface isoform, CD5-E1A, or the intracellular isoform, CD5-E1B, were generated and compared to normal B cells (CD5 blood B cells, CD5 cord blood B cells and CD5 from B chronic lymphocytic leukaemia), T cells and CD5 transfected HepG2 cells.
Based on the observation that NFAT2 is constitutively present in the nucleus of CD5 B cells and that STAT3 is phosphorylated in its S727, we have tested the implication of these two TFs on the expression of IL-10. First, using specific inhibitors-like cyclosporine A (NFATs inhibitor) and AG490 (Jak-2/STATs inhibitor) that abrogate IL-10 expression in CD5 B cells. Second, using a chromatin immunoprecipitation assay to reveal that both TFs bind the IL-10 enhancer in CD5 B cells. Interestingly, NFAT2/STAT3 activation is not restricted to IL-10 since we observed that IL-5 and IL-13 promoters recruits NFAT2/STAT3 and express both transcripts in CD5 B cells. Finally, such effect is restricted to CD5 B cells because it was not observed in T cells and CD5-transfected HepG2 cells.
Results indicate that constitutive calcineurine/NFAT2 and Jak2/STAT3 pathways contribute to cytokine type 2 expression in CD5 B cells. This observation provides new directions to polarise the immune system.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.